SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Depotech(depo)
DEPO 7.300+1.7%Aug 14 5:00 PM EST
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Dr. John M. de Castro who wrote (741)3/2/1998 11:50:00 PM
From: Czechsinthemail  Read Replies (2) of 887
 
John,

Thank you for your follow-up on arachnoiditis. A few questions:
Does this data come from DepoTech and perhaps contain various DEPO biases?
Do you know if the arachnoiditis is affected by dosage or frequency of use?
Is DepoCyt more likely to require Dexamethasone than Methotrexate? And are the side effects accompanying Dexamethasone serious enough that this might negatively affect the view of DepoCyt?
It seems like generally good news for DEPO if their primary hurdle will will be establishing efficacy for DepoCyt.

Thanks again,
Baird
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News